While historically listed with an "unknown status," recent data releases in late 2025 and early 2026 have clarified the safety profile that helped justify the Category 1 reclassification. Study Design: A randomized, placebo-controlled, double-blind Phase 1 pilot study
Tavares, A
Distribution and metabolism of delta sleep-inducing peptide in mouse brain
doi:10.1017/neu.2019.35
Key Research Areas for the Wolverine Stack Dual-phase tissue repair pathway studies vascular/ECM organisation (BPC-157) and cellular migration/cytoskeletal reconstruction (TB-500) Musculoskeletal healing pathway research tendon, ligament, muscle, and connective tissue models Angiogenesis studies VEGF/VEGFR2 upregulation, vascular tube formation, capillary network organisation Fibroblast migration, adhesion, and ECM stabilisation assays Stem/progenitor cell mobilisation and tissue-site differentiation studies Anti-inflammatory and anti-oxidative stress pathway research TNF-, IL-6, reactive oxygen species modulation Collagen synthesis, fibre alignment, and organisational quality studies Combination vs